Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kailash Mosalpuria (NPI 1669636643)

Field	Value
Entity Type	Individual
Organization	Kailash Mosalpuria
Address	4004 Pioneer Woods Dr
City	Lincoln
State	NE
ZIP	68506
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 18, 2008

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology physician with a clear infusion-heavy oncology practice: the top revenue drivers are high-cost monoclonal and immunotherapy agents (J9271, J9144, J9299), and the code mix includes chemotherapy administration (96413, 96365, 96401) and supportive biologics (pegfilgrastim, epoetin, immune globulin). The presence of both drug J-codes and infusion/administration CPTs indicates on-site infusion services and routine management of systemic cancer therapy rather than a primarily procedural or inpatient focus.

Medicare is effectively the sole payer on file: total Medicare revenue is $2.9M while there is no Medicaid billing on file, so this provider operates as a single-payer (Medicare) practice in the dataset. That concentration implies revenue exposure tied to Medicare reimbursement and utilization patterns rather than a mixed payer balance.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 65.7% of this provider’s total Medicare revenue, driven primarily by J9271 ($799.8K, 29.3%), J9144 ($513K, 18.8%), and J9299 ($481.4K, 17.6%). This concentration means a majority of revenue depends on a small set of high-cost oncology drugs rather than a broad base of lower-cost services.

Competitive standing on the top oncology drugs is modest rather than dominant: J9271 ranks #479 of 1841 nationally (74th percentile; typical, unremarkable volume for this code), J9144 ranks #117 of 615 (81th percentile; typical, unremarkable volume for this code), and J9299 ranks #163 of 505 (68th percentile; typical, unremarkable volume for this code). These percentiles indicate the provider bills these drugs at volumes above some peers but is not a market leader among national specialists for any of these agents.

Certain ancillary and office services show relatively high utilization compared with national peers: 99214 has 778 claims and $70.8K revenue and is characterized as "notably above typical national volume for this code," while common labs (85025, 80053) and blood draws (36415) appear in the top-25 with high percentile placements yet are described in the dataset as "typical, unremarkable volume for this code." This pattern suggests a busy outpatient clinic that performs frequent monitoring and problem-focused visits alongside infusion care.

The provider’s tenure is well established: NPI enumeration date is 2008-07-18 (~18 years ago), indicating long-term presence in the Medicare market. That longevity supports continuity of an infusion-centered oncology practice and may correlate with steady referral and treatment patterns.

Supportive care and biosimilars are a meaningful part of the mix: codes for pegfilgrastim (Q5108, Q5106, J2506), epoetin alfa (J0885, Q5106), and immune globulin (J1569) appear in the top-25 and together represent routine management of chemotherapy-related cytopenias and supportive needs. The presence of both branded biologics and biosimilars indicates the practice administers a range of growth factors and supportive agents as part of its oncology care pathway.

From a payer-risk and business-line perspective, dependence on a few high-cost oncology agents (65.7% of Medicare revenue from the top three codes) creates financial sensitivity to utilization or reimbursement changes for these specific drugs. While the provider is not an outlier as a national volume leader for those drugs, the combination of concentrated drug revenue and high outpatient visit intensity (e.g., 99214) defines a practice profile that is specialized, Medicare-centric, and infusion-service dependent.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

88 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,600	$40	$799.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	13,500	$40	$513K
J9299	Injection, nivolumab, 1 mg	20,060	$20	$481.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	5,980	$40	$215.3K
J0897	Injection, denosumab, 1 mg	10,560	$20	$190.1K
J1439	Injection, ferric carboxymaltose, 1 mg	75,750	$1	$75.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	780	$90	$70.8K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	2,470	$20	$54.3K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	480	$100	$45.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	480	$100	$45.3K

Showing 1–10 of 88

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Kailash Mosalpuria — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

88 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	30	14,400	$40	$671.6K
J9299	4	10	19,300	$20	$444.5K
J9144	2	10	10,440	$40	$434.6K
J1569	5	10	5,980	$40	$224.3K
Q5118	3	10	2,540	$20	$66.9K
J0897	11	200	2,040	$20	$62.7K
J2506	14	20	460	$90	$40.5K
Q5130	2	10	170	$160	$36.8K
Q5108	2	10	410	$90	$35.7K
J1439	1	30	25,880	$1	$26.4K

Showing 1–10 of 88

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kailash Mosalpuria, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0
Sakeer Hussain	IA	Hematology & Oncology Physician	$1.9M	$0
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0
Haris Zahoor	TX	Medical Oncology Physician	$1.6M	$0
Wallace Peterson	NE	Hematology & Oncology Physician	$1.5M	$0
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Kailash Mosalpuria, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Integrated Behavioral Health Services	NE	Community/Behavioral Health Agency	$0	$16.3M
Nebraska Emergency Medicine PC	NE	Emergency Medicine Physician	$0	$14.9M
Firstcare Home Health Of Eastern Nebraska, Inc	NE	Home Health Agency	$0	$6.6M
Matthew Wood	NE	Ophthalmology Physician	$3.9M	$0
Daniel Chruscicki	NE	Ophthalmology Physician	$3M	$0
Integrated Cardiology Group LLC	NE	Cardiovascular Disease Physician	$0	$2.7M
Pathology Medical Services PC	NE	Anatomic Pathology & Clinical Pathology Physician	$0	$2.1M
Rockledge Smiles LLC	NE	General Practice Dentistry	$0	$2.1M
Eye Surgical Associates, LLC	NE	Ophthalmology Physician	$0	$1.7M

Kailash Mosalpuria — Billing Profile & Reimbursement Data

Sign up for Kailash Mosalpuria — Billing Profile & Reimbursement Data policy alerts

Kailash Mosalpuria — Billing Profile & Reimbursement Data

Sign up for Kailash Mosalpuria — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References